In advanced non-small cell lung cancer, Summit Therapeutics’ ivonescimab appears to be 49% more effective at reducing the risk of disease progression or death versus Merck’s Keytruda in a late-stage study. However, analysts contend the caveat is that the trial was conducted in an entirely Chinese patient population.
The company, which is developing peptide therapies for treating endocrine and metabolic disorders, including obesity, said on Monday it was seeking a valuation of up to $482.5 million in its initial public offering in the United States.
Terns Pharmaceuticals said its oral obesity drug reduced weight by an average of 4.9% in an early stage study, joining drugmakers vying for a share of the lucrative obesity treatment market and sending its shares up 20% on Monday.
GSK’s twice-yearly depemokimab reduced asthma attacks by half and cut clinic visits by nearly three-quarters, positioning it for an estimated $4 billion in peak sales if approved.
Follow-up data from the MARIPOSA study show a favorable overall survival trend versus Tagrisso in EGFR-mutated advanced non-small cell lung cancer. The findings come just weeks after the Rybrevant-Lazcluze combination was approved for the first-line treatment.
Clients will now have access to a full range of commercialization services on a time-of-need basis supported by a hand-picked team of talented professionals with specific expertise relevant to the disease, approaches to treatment, competitive landscape, evidence generation and dissemination, and value proposition of their new treatment.